*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.
Krystal Biotech's upcoming earnings report is poised to capture attention, particularly as the company navigates its growth trajectory with a market cap of approximately $5.67 billion. Analysts are anticipating an EPS of $1.09, with revenue projected at $93.19 million, reflecting the company's continued focus on advancing its gene therapy pipeline. The whisper number, slightly lower at $1.00, suggests a cautious optimism among investors, potentially due to the absence of recent news which leaves room for surprises. As Krystal Biotech prepares to release its financial results on November 3, stakeholders will be keenly observing how the company balances its strategic investments in research and development with its revenue growth, especially in a sector where innovation is key to maintaining competitive advantage.
Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company is headquartered in Pittsburgh, Pennsylvania.
Website: https://www.krystalbio.com
Average Sentiment Score:
Overall Sentiment: